Core Viewpoint - Taimei Medical Technology (02576) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Group 1 - The company has applied to convert a total of 363 million domestic shares into H-shares for listing on the Hong Kong Stock Exchange (HKEX) [1] - The conversion and listing will occur once all necessary approvals and filings from regulatory bodies, including the CSRC and HKEX, are obtained [1] - According to the company's articles of association, there is no requirement to hold a shareholders' meeting to approve the conversion and listing [1]

Core Viewpoint - Taimei Medical Technology (02576) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Group 1: Company Actions - The company has applied to convert a total of 363 million domestic shares into H-shares for listing on the Hong Kong Stock Exchange (HKEX) [1] - The conversion and listing will occur once all necessary approvals and compliance with applicable laws and regulations are obtained from relevant regulatory bodies, including the CSRC and HKEX [1] - According to the company's articles of association, there is no requirement to hold a shareholders' meeting to approve the conversion and listing [1]

浙江太美醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2576） 內幕消息 本公司建議實施H股全流通 本公告由浙江太美醫療科技股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證 券及期貨條例第XIVA部項下的內幕消息條文（定義見上市規則）作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Zhejiang Taimei Medical Technology Co., Ltd. 1 轉換及上市乃視乎中國證監會、聯交所及其他相關境內外監管機構要求的其他相 關程序的落實情況而定。本公司股東及潛在投資者於買賣本公司證券時務請審慎 行事。 承董事會命 浙江太美醫療科技股份有限公司 董事長 趙璐先生 香港，2025年9月29日 茲提述(i)中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈並於 2023年8月10日修訂 ...

[Company Information](index=3&type=section&id=Company%20Information) [Board of Directors and Committees](index=3&type=section&id=2.1%20Board%20of%20Directors%20and%20Committees) This section details the composition of Zhejiang Taimei Medical Technology Co., Ltd.'s Board of Directors, including executive and independent non-executive directors, and its key committees - The Board of Directors comprises executive directors (including Chairman Mr. Zhao Lu) and independent non-executive directors[6](index=6&type=chunk) - The company has established an Audit Committee, Remuneration and Appraisal Committee, Nomination Committee, and Supervisory Committee, with their respective chairpersons and members specified[6](index=6&type=chunk) [Corporate Contact and Legal Advisors](index=3&type=section&id=2.2%20Corporate%20Contact%20and%20Legal%20Advisors) This section provides key contact information for the company, including auditors, company secretaries, registered offices, principal places of business, and stock code - The auditor is PricewaterhouseCoopers, and the joint company secretaries are Ms. Ni Xiaomei and Mr. Pan Bingyang[6](index=6&type=chunk) - The company's headquarters are in Jiaxing, Zhejiang Province, China, with its principal place of business in Hong Kong located at Golden Centre, Des Voeux Road Central[6](index=6&type=chunk) - The stock code is **2576**, and the company website is www.taimei.com[7](index=7&type=chunk) [Definitions](index=5&type=section&id=Definitions) [Definitions of Key Terms](index=5&type=section&id=3.1%20Definitions%20of%20Key%20Terms) This section defines key terms and abbreviations used in the interim report, covering company entities, industry terminology, regulatory standards, and AI-driven product names - “The Company” or “Taimei Medical Technology” refers to Zhejiang Taimei Medical Technology Co., Ltd. and its predecessors[8](index=8&type=chunk) - “The Group” or “We” refers to the Company and its subsidiaries[8](index=8&type=chunk) Definitions of Key Industry Terms and AI Products | Term | Definition | | :--- | :--- | | CRO | Contract Research Organization, providing drug development services to pharmaceutical companies | | HIPAA | U.S. Health Insurance Portability and Accountability Act, protecting patient medical information privacy and security | | ICH-GCP | International Conference on Harmonisation - Good Clinical Practice, quality management standards for clinical trials of medicinal products | | iCTA | Intelligent Clinical Trial Assistant, an AI-powered agent for intelligent classification, quality control, and naming of trial documents | | iDM | Intelligent Data Manager, an AI-driven automation technology to improve data management efficiency and quality | | iPV | Intelligent Pharmacovigilance, an AI-powered agent for automated processing of individual safety reports, supporting multinational regulatory submissions | | IRC | Independent Review Committee, providing impartial review and analysis of clinical trial imaging data | | PDPA | Personal Data Protection Act, regulating the collection, use, and disclosure of personal data | | SaaS | Software as a Service | | SMO | Site Management Organization, assisting clinical trial sites with specific operational tasks | [Financial Highlights](index=10&type=section&id=Financial%20Highlights) [Overview of Key Financial Indicators](index=10&type=section&id=4.1%20Overview%20of%20Key%20Financial%20Indicators) This section summarizes key financial data for the six months ended June 30, 2025, showing decreased revenue and gross profit, significantly narrowed operating and period losses, and reduced total assets and liabilities Key Financial Data for the Six Months Ended June 30 | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 244,221 | 272,784 | -10.5 | | Gross Profit | 100,188 | 110,944 | -9.7 | | Operating Loss | (48,710) | (191,995) | -74.6 | | Loss for the Period | (29,309) | (175,317) | -83.3 | | Adjusted Net Loss (Non-IFRS Measure) | (28,696) | (49,253) | -41.7 | Balance Sheet Data as of June 30, 2025 and December 31, 2024 | Indicator | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | Change (RMB '000) | | :--- | :--- | :--- | :--- | | Total Assets | 1,518,520 | 1,583,197 | (64,677) | | Total Liabilities | 302,104 | 348,624 | (46,520) | | Equity Attributable to Owners of the Company | 1,146,000 | 1,157,810 | (11,810) | | Cash and Cash Equivalents | 253,013 | 319,297 | (66,284) | [Management Discussion and Analysis](index=11&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=11&type=section&id=(I)%20Business%20Review) For the six months ended June 30, 2025, the Group's revenue decreased by **10.5%** to **RMB 244.2 million**, primarily due to reduced digital services income, while gross profit declined, gross margin slightly improved, and losses significantly narrowed Revenue and Profit Overview for the Six Months Ended June 30 | Indicator | 2025 (RMB million) | 2024 (RMB million) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 244.2 | 272.8 | -10.5 | | Gross Profit | 100.2 | 110.9 | -9.7 | | Gross Margin | 41.0% | 40.7% | +0.3 pp | | Loss for the Period | (29.3) | (175.3) | -83.3 | | Adjusted Net Loss | (28.7) | (49.3) | -41.7 | - The company provides solutions for the pharmaceutical and medical device industries, including cloud software (SaaS products, customized products) and digital services, primarily through the "Trials R&D Collaboration Platform" and "PharmaOS Pharmaceutical Digital Marketing Platform," partially enabled by the Vence AI platform[17](index=17&type=chunk)[21](index=21&type=chunk)[22](index=22&type=chunk) - In the first half of 2025, cloud software revenue accounted for **38.7%** of operating revenue, while digital services revenue accounted for **61.2%**[23](index=23&type=chunk)[26](index=26&type=chunk) [Business Outlook and Prospects](index=14&type=section&id=(II)%20Business%20Outlook%20and%20Prospects) The company will enhance AI R&D, launching a "Clinical Research Digital Intelligence Evolution Blueprint" and "Digital Employee" system to integrate AI models with SaaS platforms, aiming to implement an AIaaS collaboration model and expand globally through data and delivery centers in China, the US, and Singapore - In the first half of 2025, the company officially released its "Clinical Research Digital Intelligence Evolution Blueprint," introducing an AIaaS (AI as a service) collaboration model through deep integration of large AI models with SaaS platforms[28](index=28&type=chunk) - The company pioneered a "Digital Employee" system, embedding AI agents across the entire clinical research process to boost productivity; for instance, iDM (Intelligent Data Manager) can improve database creation efficiency by **80%**, iCTA (Intelligent Clinical Trial Assistant) can reduce attribute filling time by **70%**, and iPV (Intelligent Pharmacovigilance) can increase efficiency by **300%**[28](index=28&type=chunk)[29](index=29&type=chunk) - The company plans to leverage the "Digital Employee" system as a core driver to implement the AIaaS business model, billing based on "task volume + effect" and enhancing products and services through data security and compliance expertise[30](index=30&type=chunk) - International expansion is underway, with three data and delivery centers established in China, the US, and Singapore, and multiple international certifications such as HIPAA, PDPA, and ICH-GCP obtained, aiming to meet client demands for high-quality and efficient global multi-center clinical research[31](index=31&type=chunk) [Financial Review](index=16&type=section&id=(III)%20Financial%20Review) This section reviews the Group's financial performance for the six months ended June 30, 2025, noting a **10.5%** revenue decrease, reduced gross profit with a slight margin increase, significant declines in operating expenses, and substantial narrowing of losses, alongside improved liquidity ratios Revenue Breakdown for the Six Months Ended June 30 | Revenue Source | 2025 (RMB '000) | 2024 (RMB '000) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Cloud Software - SaaS Products | 82,425 | 81,564 | 1.1 | | Cloud Software - Customized Products | 12,171 | 15,993 | -23.9 | | **Cloud Software Subtotal** | **94,596** | **97,557** | **-3.0** | | Digital Services | 149,371 | 175,227 | -14.8 | | Others | 254 | – | Not applicable | | **Total** | **244,221** | **272,784** | **-10.5** | - Cost of sales decreased by **11.0%** year-on-year to **RMB 144.0 million**, primarily due to improved labor efficiency and reduced revenue[35](index=35&type=chunk) - Gross profit decreased by **9.7%** year-on-year to **RMB 100.2 million**, with the gross margin slightly increasing from **40.7%** to **41.0%**[36](index=36&type=chunk) Major Expense Changes for the Six Months Ended June 30 | Expense Category | 2025 (RMB '000) | 2024 (RMB '000) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Selling Expenses | 37,573 | 51,158 | -26.6 | | Administrative Expenses | 57,679 | 217,186 | -73.4 | | Research and Development Expenses | 37,705 | 50,924 | -26.0 | - The significant reduction in administrative expenses was primarily due to a **RMB 121.3 million** decrease in share-based payments and a **RMB 30.3 million** reduction in staff costs[38](index=38&type=chunk) - Other income decreased from **RMB 9.8 million** to **RMB 2.4 million**, mainly due to a **RMB 6.8 million** reduction in government grants[41](index=41&type=chunk) - A net other loss of **RMB 12.9 million** was recorded (compared to a net gain of **RMB 7.8 million** in the same period of 2024), primarily impacted by a net foreign exchange loss of **RMB 16.1 million**[43](index=43&type=chunk) - Loss for the period decreased by **83.3%** from **RMB 175.3 million** to **RMB 29.3 million**[45](index=45&type=chunk) - Adjusted net loss (non-IFRS measure) was **RMB 28.7 million**, a year-on-year decrease of **41.7%**[16](index=16&type=chunk)[47](index=47&type=chunk) Liquidity Ratios | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Current Ratio | 5.66 | 5.05 | | Debt-to-Asset Ratio | 19.9% | 22.0% | [Other Financial Information](index=20&type=section&id=(IV)%20Other%20Financial%20Information) This section covers the Group's significant investment plans, contingent liabilities, capital commitments, off-balance sheet commitments, and employee remuneration, noting no major activities or liabilities during the reporting period and proper allocation of global offering proceeds - During the reporting period and up to the report date, the Group had no other significant investment and capital asset plans, nor any material acquisitions or disposals of subsidiaries, associates, and joint ventures[55](index=55&type=chunk)[56](index=56&type=chunk) - As of June 30, 2025, the Group had no material contingent liabilities, capital commitments, or off-balance sheet commitments and arrangements[57](index=57&type=chunk)[58](index=58&type=chunk)[59](index=59&type=chunk) Employee Functional Distribution as of June 30, 2025 | Function | Number of Employees | Percentage of Total (%) | | :--- | :--- | :--- | | R&D | 127 | 19.4 | | Sales & Marketing | 85 | 13.0 | | Professional & Technical Staff | 359 | 54.7 | | Administrative | 85 | 13.0 | | **Total** | **656** | **100.0** | - For the six months ended June 30, 2025, total staff costs amounted to **RMB 152.1 million**, a year-on-year decrease[60](index=60&type=chunk) Use of Net Proceeds from Global Offering (as of June 30, 2025) | Intended Use of Net Proceeds | Allocated (HKD million) | Approximate Percentage of Total Net Proceeds (%) | Utilized (HKD million) | Unutilized (HKD million) | Planned Utilization Schedule | | :--- | :--- | :--- | :--- | :--- | :--- | | Improvement and Upgrade of Platform and Cloud Software | 90.8 | 35% | 9.2 | 81.6 | Before December 31, 2029 | | Enhancement of Core Technologies and R&D Capabilities | 77.9 | 30% | 5.7 | 72.2 | Before December 31, 2029 | | Strengthening Sales and Marketing Capabilities | 26.0 | 10% | 0.7 | 25.3 | Before December 31, 2029 | | Selectively Seeking Strategic Investments and Acquisitions | 38.9 | 15% | 0 | 38.9 | Before December 31, 2029 | | Working Capital and General Corporate Purposes | 25.9 | 10% | 3.1 | 22.9 | Before December 31, 2029 | | **Total** | **259.5** | **100%** | **18.7** | **240.8** | | [Other Information](index=22&type=section&id=Other%20Information) [Interim Dividend and Corporate Governance](index=22&type=section&id=5.1%20Interim%20Dividend%20and%20Corporate%20Governance) The Board does not recommend an interim dividend for the six months ended June 30, 2025, intending to retain future earnings for operations and business expansion, while maintaining high corporate governance standards in compliance with listing rules - The Board does not recommend the payment of an interim dividend for the reporting period (2024: nil)[64](index=64&type=chunk) - The company expects to retain all future earnings for operations and business expansion, currently having no dividend policy[66](index=66&type=chunk) - The Group is committed to maintaining high standards of corporate governance and has complied with all applicable code provisions of the Corporate Governance Code[65](index=65&type=chunk) [Securities Transactions and Audit Committee](index=22&type=section&id=5.2%20Securities%20Transactions%20and%20Audit%20Committee) The company has adopted the Model Code for securities transactions by directors, supervisors, and senior management, with all relevant personnel confirming compliance, and the Audit Committee has reviewed the interim financial results, confirming adherence to accounting standards and regulations - All directors and supervisors confirmed compliance with the Model Code set out in Appendix C3 of the Listing Rules throughout the reporting period[67](index=67&type=chunk) - For the six months ended June 30, 2025, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities[68](index=68&type=chunk) - The Audit Committee has reviewed the interim financial results for the six months ended June 30, 2025, and deemed them compliant with relevant accounting standards, rules, and regulations[69](index=69&type=chunk) [Events After Reporting Period](index=23&type=section&id=5.3%20Events%20After%20Reporting%20Period) After the reporting period, Mr. Jiang Chengwen resigned as Chief Financial Officer due to personal matters, and Mr. Wang Wei was appointed as the new Chief Financial Officer, effective July 25, 2025 - Mr. Jiang Chengwen resigned as the company's Chief Financial Officer, effective July 25, 2025[70](index=70&type=chunk) - The Board resolved to appoint Mr. Wang Wei as the company's Chief Financial Officer, effective July 25, 2025[70](index=70&type=chunk) [Interests of Directors, Supervisors and Chief Executive](index=23&type=section&id=5.4%20Interests%20of%20Directors%2C%20Supervisors%20and%20Chief%20Executive) This section discloses the interests of directors, supervisors, and the chief executive in the company's shares and related shares as of June 30, 2025, with Chairman and Executive Director Mr. Zhao Lu holding significant interests Directors' Interests in Shares (as of June 30, 2025) | Director's Name | Position | Nature of Interest | Class of Shares | Number of Shares/Related Shares Held | Approximate Percentage of Total Issued Shares (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | Mr. Zhao Lu | Chairman and Executive Director | Beneficial owner; interest in controlled corporation | Domestic Shares | 178,203,028 | 31.61 | | | | | H Shares | 1,216,500 | 0.22 | | Mr. Zhang Hongwei | Executive Director and Head of Digital Marketing Business Unit | Interest in controlled corporation | Domestic Shares | 20,312,190 | 3.60 | - As of June 30, 2025, the company had **563,779,000** shares in total, comprising **363,186,467** domestic shares and **200,592,533** H shares[74](index=74&type=chunk) [Interests of Substantial Shareholders](index=25&type=section&id=5.5%20Interests%20of%20Substantial%20Shareholders) This section lists the interests of substantial shareholders (excluding directors, supervisors, or chief executives) in the company's shares and related shares as of June 30, 2025, including Ms. Tang Lili, employee shareholding platforms, Tencent, Matrix Partners, Northern Light Venture Capital, Zheshang Venture Capital, and SoftBank-related entities Substantial Shareholders' Interests in Shares (as of June 30, 2025) | Shareholder Name | Capacity/Nature of Interest | Number of Shares Held | Approximate Percentage of Total Issued Share Capital (%) | | :--- | :--- | :--- | :--- | | Tang Lili | Interest in controlled corporation; spouse's interest | 178,203,028 Domestic Shares | 31.61 | | Shanghai Kunrui | Beneficial owner | 19,344,866 Domestic Shares | 3.43 | | Shanghai Xiaoju | Beneficial owner | 20,312,190 Domestic Shares | 3.60 | | Xinyu Shenkong | Beneficial owner | 18,204,844 Domestic Shares | 3.23 | | Oriental Power Holdings Limited | Interest in controlled corporation | 51,911,405 Domestic Shares, 12,977,851 H Shares | 9.21, 2.30 | | Tencent Holdings Limited | Interest in controlled corporation | 51,911,405 Domestic Shares, 12,977,851 H Shares | 9.21, 2.30 | | Ma Huateng | Interest in controlled corporation | 44,880,821 Domestic Shares, 11,220,205 H Shares | 7.96, 1.99 | | Matrix Partners China V (Hangzhou) Venture Capital Partnership (Limited Partnership) | Beneficial owner | 22,349,533 Domestic Shares, 28,100,879 H Shares | 3.96, 4.98 | | Zuo Lingye | Interest in controlled corporation | 23,908,953 Domestic Shares, 30,061,593 H Shares | 4.24, 5.33 | | Northern Light Venture Capital (Suzhou) Zheng Yuan Venture Capital Partnership (Limited Partnership) | Beneficial owner | 10,139,955 H Shares | 1.80 | | Zheshang Venture Capital Co., Ltd. | Beneficial owner; interest in controlled corporation | 10,094,225 H Shares | 1.79 | | Zhang Xu | Interest in controlled corporation | 12,285,138 H Shares | 2.19 | - Ms. Tang Lili, as the spouse of Mr. Zhao Lu, is deemed to have an interest in the H shares and domestic shares in which Mr. Zhao has an interest or is deemed to have an interest[81](index=81&type=chunk) [Changes in Information of Directors and Supervisors and Continuing Disclosure Obligations](index=32&type=section&id=5.6%20Changes%20in%20Information%20of%20Directors%20and%20Supervisors%20and%20Continuing%20Disclosure%20Obligations) There have been no significant changes in the information of directors and supervisors since the publication of the 2024 annual report, and the company has no other continuing disclosure obligations under Listing Rules 13.20, 13.21, and 13.22 - No changes in the information of directors and supervisors requiring disclosure under Rule 13.51B(1) of the Listing Rules have occurred since the publication date of the 2024 annual report and up to the date of this interim report[91](index=91&type=chunk) - The company has no other disclosure obligations under Rules 13.20, 13.21, and 13.22 of the Listing Rules[92](index=92&type=chunk) [Interim Financial Information Review Report](index=33&type=section&id=Interim%20Financial%20Information%20Review%20Report) [Independent Auditor's Review Conclusion](index=33&type=section&id=6.1%20Independent%20Auditor's%20Review%20Conclusion) PricewaterhouseCoopers reviewed the Group's interim financial information for the six months ended June 30, 2025, finding no matters suggesting it was not prepared in all material respects in accordance with IAS 34 - PricewaterhouseCoopers has reviewed the Group's interim financial information for the six months ended June 30, 2025[94](index=94&type=chunk) - The scope of the review is substantially less than an audit, thus no audit opinion is expressed[95](index=95&type=chunk) - Conclusion: Nothing has come to the auditor's attention that causes them to believe the interim financial information is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting"[96](index=96&type=chunk) [Interim Condensed Consolidated Statement of Profit or Loss](index=34&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) [Profit or Loss Performance for the Six Months Ended June 30, 2025](index=34&type=section&id=7.1%20Profit%20or%20Loss%20Performance%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) For the six months ended June 30, 2025, the Group's revenue was **RMB 244,221 thousand**, a **10.5%** year-on-year decrease, with gross profit at **RMB 100,188 thousand**, operating loss at **RMB (48,710) thousand**, and loss for the period significantly narrowed to **RMB (29,309) thousand** Interim Condensed Consolidated Statement of Profit or Loss (for the Six Months Ended June 30) | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Revenue | 244,221 | 272,784 | | Cost of Sales | (144,033) | (161,840) | | Gross Profit | 100,188 | 110,944 | | Selling Expenses | (37,573) | (51,158) | | Administrative Expenses | (57,679) | (217,186) | | Research and Development Expenses | (37,705) | (50,924) | | Operating Loss | (48,710) | (191,995) | | Loss for the Period | (29,309) | (175,317) | | Loss Attributable to Owners of the Company | (22,802) | (171,126) | | Loss Attributable to Non-controlling Interests | (6,507) | (4,191) | | Basic and Diluted Loss Per Share (RMB) | (0.04) | (0.32) | [Interim Condensed Consolidated Statement of Comprehensive Loss](index=35&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Loss) [Comprehensive Loss Performance for the Six Months Ended June 30, 2025](index=35&type=section&id=8.1%20Comprehensive%20Loss%20Performance%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) For the six months ended June 30, 2025, the Group's loss for the period significantly decreased to **RMB (29,309) thousand**, with total comprehensive loss for the period narrowing to **RMB (18,770) thousand** after considering exchange differences from translating overseas operations Interim Condensed Consolidated Statement of Comprehensive Loss (for the Six Months Ended June 30) | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Loss for the Period | (29,309) | (175,317) | | Exchange differences arising from translation of overseas operations | 10,539 | (2,098) | | Other comprehensive income/(loss) for the period (net of tax) | 10,539 | (2,098) | | Total comprehensive loss for the period | (18,770) | (177,415) | | Total comprehensive loss for the period attributable to owners of the Company | (12,423) | (173,240) | | Total comprehensive loss for the period attributable to non-controlling interests | (6,347) | (4,175) | [Interim Condensed Consolidated Statement of Financial Position](index=36&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) [Financial Position as of June 30, 2025](index=36&type=section&id=9.1%20Financial%20Position%20as%20of%20June%2030%2C%202025) As of June 30, 2025, the Group's total assets were **RMB 1,518,520 thousand**, slightly down from December 31, 2024, with increased short-term bank deposits offsetting decreased cash and cash equivalents, while total liabilities and total equity also decreased Interim Condensed Consolidated Statement of Financial Position (as of June 30, 2025) | Indicator | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | | :--- | :--- | :--- | | **Assets** | | | | Non-current assets | 96,304 | 106,097 | | Current assets | 1,422,216 | 1,477,100 | | **Total assets** | **1,518,520** | **1,583,197** | | **Equity** | | | | Equity attributable to owners of the Company | 1,146,000 | 1,157,810 | | Non-controlling interests | 70,416 | 76,763 | | **Total equity** | **1,216,416** | **1,234,573** | | **Liabilities** | | | | Non-current liabilities | 50,696 | 56,032 | | Current liabilities | 251,408 | 292,592 | | **Total liabilities** | **302,104** | **348,624** | | **Total equity and liabilities** | **1,518,520** | **1,583,197** | - Short-term bank deposits within current assets increased from **RMB 599,920 thousand** to **RMB 736,071 thousand**, while cash and cash equivalents decreased from **RMB 319,297 thousand** to **RMB 253,013 thousand**[102](index=102&type=chunk) [Interim Condensed Consolidated Statement of Changes in Equity](index=38&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity) [Changes in Equity for the Six Months Ended June 30, 2025](index=38&type=section&id=10.1%20Changes%20in%20Equity%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) For the six months ended June 30, 2025, the Group's total equity decreased from **RMB 1,234,573 thousand** to **RMB 1,216,416 thousand**, primarily due to a loss for the period of **RMB (29,309) thousand**, partially offset by exchange differences and share-based payments Interim Condensed Consolidated Statement of Changes in Equity (for the Six Months Ended June 30) | Indicator | Share Capital (RMB '000) | Other Reserves (RMB '000) | Currency Translation Reserve (RMB '000) | Accumulated Losses (RMB '000) | Total (RMB '000) | Non-controlling Interests (RMB '000) | Total Equity (RMB '000) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | As of January 1, 2025 | 563,779 | 2,295,189 | 1,919 | (1,703,077) | 1,157,810 | 76,763 | 1,234,573 | | Loss for the period | – | – | – | (22,802) | (22,802) | (6,507) | (29,309) | | Exchange differences arising from translation of overseas operations | – | – | 10,379 | – | 10,379 | 160 | 10,539 | | Share-based payments | – | 613 | – | – | 613 | – | 613 | | **As of June 30, 2025** | **563,779** | **2,295,802** | **12,298** | **(1,725,879)** | **1,146,000** | **70,416** | **1,216,416** | [Interim Condensed Consolidated Statement of Cash Flows](index=39&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) [Cash Flow Analysis for the Six Months Ended June 30, 2025](index=39&type=section&id=11.1%20Cash%20Flow%20Analysis%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) For the six months ended June 30, 2025, the Group's cash and cash equivalents decreased by **RMB 64,274 thousand**, with a significantly reduced net cash used in operating activities and a shift to net cash inflow from investing activities Interim Condensed Consolidated Statement of Cash Flows (for the Six Months Ended June 30) | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Net cash used in operating activities | (47,927) | (132,927) | | Net cash from/(used in) investing activities | 218 | (304,455) | | Net cash used in financing activities | (16,565) | (15,394) | | Net decrease in cash and cash equivalents | (64,274) | (452,776) | | Cash and cash equivalents at end of period | 253,013 | 65,934 | - Net cash used in operating activities significantly decreased from **RMB (132,927) thousand** in the same period of 2024 to **RMB (47,927) thousand** in 2025[107](index=107&type=chunk) - Investing activities shifted from a net outflow of **RMB (304,455) thousand** in the same period of 2024 to a net inflow of **RMB 218 thousand** in 2025, primarily due to changes in deposits and redemptions of short-term bank deposits[107](index=107&type=chunk) [Notes to the Interim Condensed Consolidated Financial Information](index=40&type=section&id=Notes%20to%20the%20Interim%20Condensed%20Consolidated%20Financial%20Information) [General Information](index=40&type=section&id=12.1%20General%20Information) Zhejiang Taimei Medical Technology Co., Ltd., established in China in 2013 and listed on the HKEX in 2024, primarily provides life science R&D and marketing digitalization solutions in China and overseas, with Mr. Zhao Lu as the ultimate controlling shareholder - The company was established in China on June 6, 2013, completed its share restructuring on September 11, 2020, and was listed on the Main Board of the Hong Kong Stock Exchange on October 8, 2024[108](index=108&type=chunk)[110](index=110&type=chunk) - The Group is primarily engaged in providing life science R&D and marketing digitalization solutions[108](index=108&type=chunk) - The ultimate controlling shareholder of the Group is Mr. Zhao Lu[109](index=109&type=chunk) [Basis of Preparation](index=40&type=section&id=12.2%20Basis%20of%20Preparation) This condensed consolidated interim financial information is prepared in accordance with IAS 34 "Interim Financial Reporting" and should be read in conjunction with the Group's consolidated financial statements for the year ended December 31, 2024 - The condensed consolidated interim financial information has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting"[111](index=111&type=chunk) - This report should be read in conjunction with the Group's consolidated financial statements for the year ended December 31, 2024[111](index=111&type=chunk) [New Standards and Interpretations](index=41&type=section&id=12.3%20New%20Standards%20and%20Interpretations) The Group first applied IAS 21 (amended) "Lack of Exchangeability" for the fiscal year beginning January 1, 2025, with no significant impact on the interim financial information, and other unadopted new standards are not expected to have a material effect - The Group first applied IAS 21 (amended) "Lack of Exchangeability" for the fiscal year beginning January 1, 2025, which had no significant impact[113](index=113&type=chunk)[114](index=114&type=chunk) - Other amendments to existing standards not yet adopted are not expected to have a material impact on the Group's condensed consolidated interim financial information[115](index=115&type=chunk) [Fair Value Measurement of Financial Instruments](index=42&type=section&id=12.4%20Fair%20Value%20Measurement%20of%20Financial%20Instruments) This section outlines the Group's fair value measurement of financial instruments across three levels, with warrant liabilities classified as Level 3 and sensitive to changes in discount rates as of June 30, 2025 Fair Value Hierarchy of Financial Instruments (as of June 30, 2025) | Indicator | Level 1 (RMB '000) | Level 2 (RMB '000) | Level 3 (RMB '000) | Total (RMB '000) | | :--- | :--- | :--- | :--- | :--- | | Warrant liabilities | – | – | 35,318 | 35,318 | Fair Value Hierarchy of Financial Instruments (as of December 31, 2024) | Indicator | Level 1 (RMB '000) | Level 2 (RMB '000) | Level 3 (RMB '000) | Total (RMB '000) | | :--- | :--- | :--- | :--- | :--- | | Financial assets at fair value through profit or loss | – | – | 120,792 | 120,792 | | Warrant liabilities | – | – | 35,347 | 35,347 | - If the discount rate for warrant liabilities decreased/increased by **1%**, the loss before income tax for the six months ended June 30, 2025, would increase/decrease by approximately **RMB 344,000**, respectively[123](index=123&type=chunk) [Segment Information](index=46&type=section&id=12.5%20Segment%20Information) The Group operates and is managed as a single segment, thus no segment information is presented, with no single external customer accounting for 10% or more of revenue, and both revenue and non-current assets primarily originating from mainland China - The Group's operations are managed as a single segment, and therefore no segment information is presented[124](index=124&type=chunk) - For the six months ended June 30, 2025, no revenue from transactions with a single external customer accounted for **10%** or more of the Group's revenue[125](index=125&type=chunk) Consolidated Total Revenue by Customer Location (for the Six Months Ended June 30) | Region | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Mainland China | 238,577 | 267,292 | | South Korea | 1,058 | 2,292 | | Singapore | 1,872 | 1,750 | | Europe | 1,360 | 1,030 | | Others | 1,354 | 420 | | **Total** | **244,221** | **272,784** | - As of June 30, 2025, total non-current assets amounted to **RMB 84,465 thousand**, with **RMB 83,283 thousand** located in mainland China[127](index=127&type=chunk) [Revenue](index=47&type=section&id=12.6%20Revenue) For the six months ended June 30, 2025, the Group's revenue was **RMB 244,221 thousand**, primarily from digital services and cloud software products, with most revenue recognized over time, and contract assets increasing while contract liabilities decreased Revenue Breakdown (for the Six Months Ended June 30) | Revenue Source | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Cloud Software Products - SaaS Products | 82,425 | 81,564 | | Cloud Software Products - Customized Products | 12,171 | 15,993 | | Digital Services | 149,371 | 175,227 | | Other Services | 254 | – | | **Total** | **244,221** | **272,784** | - By timing of revenue recognition, **RMB 238,162 thousand** was recognized over time, and **RMB 6,059 thousand** was recognized at a point in time[128](index=128&type=chunk) - Contract assets increased from **RMB 16,614 thousand** as of December 31, 2024, to **RMB 19,722 thousand** as of June 30, 2025[129](index=129&type=chunk) - Contract liabilities decreased from **RMB 86,699 thousand** as of December 31, 2024, to **RMB 69,699 thousand** as of June 30, 2025[130](index=130&type=chunk) [Expenses by Nature](index=49&type=section&id=12.7%20Expenses%20by%20Nature) For the six months ended June 30, 2025, the Group's total expenses significantly decreased to **RMB 276,990 thousand** from **RMB 481,108 thousand** in the prior year, primarily due to reduced employee benefits and the absence of share compensation and listing expenses present in the previous period Analysis of Expenses by Nature (for the Six Months Ended June 30) | Expense Category | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Employee benefit expenses (excluding share-based payments) | 152,050 | 209,643 | | Clinical research related costs | 70,322 | 74,207 | | IT infrastructure and data service costs | 14,423 | 17,728 | | Office, business development and travel expenses | 11,708 | 12,749 | | Consultancy and professional service fees | 6,827 | 3,666 | | Depreciation of right-of-use assets | 5,223 | 13,045 | | Depreciation of property, plant and equipment | 3,068 | 10,609 | | Amortisation of intangible assets | 2,115 | 2,107 | | Short-term lease expenses | 644 | 757 | | Share-based payments | 613 | 22,242 | | Share compensation to certain shareholders | – | 92,836 | | Listing expenses related to global offering | – | 10,986 | | Other expenses | 9,997 | 10,533 | | **Total** | **276,990** | **481,108** | [Other Income](index=50&type=section&id=12.8%20Other%20Income) For the six months ended June 30, 2025, the Group's other income significantly decreased to **RMB 2,445 thousand** from **RMB 9,824 thousand** in the prior year, primarily due to a **RMB 6,807 thousand** reduction in government grants Other Income Breakdown (for the Six Months Ended June 30) | Income Source | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Government grants | 1,734 | 8,541 | | Others | 711 | 1,283 | | **Total** | **2,445** | **9,824** | - Government grants received during the period primarily comprised financial subsidies from various local government authorities in mainland China[132](index=132&type=chunk) [Other (Losses)/Gains, Net](index=50&type=section&id=12.9%20Other%20(Losses)%2FGains%2C%20Net) For the six months ended June 30, 2025, the Group recorded a net other loss of **RMB 12,932 thousand**, a shift from a net gain of **RMB 7,849 thousand** in the prior year, primarily driven by a net foreign exchange loss of **RMB 16,075 thousand** Other (Losses)/Gains, Net Breakdown (for the Six Months Ended June 30) | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Fair value gains on financial assets at fair value through profit or loss | 1,123 | 6,954 | | Net foreign exchange (losses)/gains | (16,075) | 5,275 | | Fair value gains/(losses) on warrant liabilities | 29 | (936) | | Others | 1,991 | (3,444) | | **Total** | **(12,932)** | **7,849** | [Net Finance Income](index=51&type=section&id=12.10%20Net%20Finance%20Income) For the six months ended June 30, 2025, the Group's net finance income increased to **RMB 19,401 thousand** from **RMB 16,678 thousand** in the prior year, primarily due to a **RMB 2,846 thousand** increase in interest income Net Finance Income Breakdown (for the Six Months Ended June 30) | Indicator | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Finance income - Interest income | 19,775 | 16,929 | | Finance income - Accrued income on long-term receivables | 205 | – | | Finance costs - Interest expense on bank borrowings | (130) | – | | Finance costs - Interest expense on lease liabilities | (449) | (251) | | **Net finance income** | **19,401** | **16,678** | [Income Tax Expense](index=51&type=section&id=12.11%20Income%20Tax%20Expense) The Group recorded no income tax expense for the six months ended June 30, 2025, due to a loss for the period, with eligible entities in mainland China enjoying preferential tax rates and no tax provision made for overseas subsidiaries without estimated taxable profits - For the six months ended June 30, 2025, the Group recorded no income tax expense[99](index=99&type=chunk) - Entities in mainland China qualified as "High and New Technology Enterprises" enjoy a preferential income tax rate of **15%**[135](index=135&type=chunk) - Certain subsidiaries in mainland China qualified as "Small and Micro Profit Enterprises" enjoy a preferential income tax rate of **20%**[135](index=135&type=chunk) - No income tax provision was made for subsidiaries in Singapore and the United States due to no estimated taxable profits subject to profit tax[136](index=136&type=chunk)[137](index=137&type=chunk) [Loss Per Share](index=52&type=section&id=12.12%20Loss%20Per%20Share) For the six months ended June 30, 2025, the Group's basic and diluted loss per share significantly narrowed to **RMB (0.04)** from **RMB (0.32)** in the prior year, with diluted loss per share being the same as basic loss per share due to the anti-dilutive effect of potential ordinary shares Loss Per Share (for the Six Months Ended June 30) | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | Loss attributable to owners of the Company (RMB '000) | (22,802) | (171,126) | | Weighted average number of ordinary shares in issue ('000 shares) | 563,779 | 538,000 | | **Basic loss per share (expressed in RMB per share)** | **(0.04)** | **(0.32)** | - As the Group incurred a loss for the period, potential ordinary shares were not included in the calculation of diluted loss per share, thus diluted loss per share is the same as basic loss per share[140](index=140&type=chunk) [Dividends](index=53&type=section&id=12.13%20Dividends) The company neither declared nor paid any dividends for the six months ended June 30, 2025, consistent with the prior year - For the six months ended June 30, 2025, the company neither declared nor paid any dividends (2024: nil)[141](index=141&type=chunk) [Property, Plant and Equipment](index=53&type=section&id=12.14%20Property%2C%20Plant%20and%20Equipment) The Group's net book value of property, plant, and equipment decreased to **RMB 10,295 thousand** as of June 30, 2025, from **RMB 12,201 thousand** as of December 31, 2024, primarily due to depreciation expenses, which are mainly recognized in administrative expenses - The net book value of property, plant, and equipment decreased from **RMB 12,201 thousand** as of December 31, 2024, to **RMB 10,295 thousand** as of June 30, 2025[142](index=142&type=chunk) - Total depreciation expense for the six months ended June 30, 2025, was **RMB 3,068 thousand**, of which **RMB 2,126 thousand** was recognized in administrative expenses[143](index=143&type=chunk) [Right-of-use Assets and Lease Liabilities](index=54&type=section&id=12.15%20Right-of-use%20Assets%20and%20Lease%20Liabilities) The Group's net book value of right-of-use assets (primarily leased buildings) decreased to **RMB 17,819 thousand** as of June 30, 2025, from **RMB 23,003 thousand** as of December 31, 2024, with a corresponding reduction in lease liabilities, and depreciation expenses mainly recognized in administrative expenses and cost of sales - The net book value of right-of-use assets (leased buildings) decreased from **RMB 23,003 thousand** as of December 31, 2024, to **RMB 17,819 thousand** as of June 30, 2025[145](index=145&type=chunk)[147](index=147&type=chunk) - Total lease liabilities decreased from **RMB 24,754 thousand** as of December 31, 2024, to **RMB 18,772 thousand** as of June 30, 2025[145](index=145&type=chunk) - Depreciation expense for right-of-use assets for the six months ended June 30, 2025, was **RMB 5,223 thousand**, with **RMB 1,834 thousand** recognized in administrative expenses and **RMB 1,801 thousand** in cost of sales[148](index=148&type=chunk) [Intangible Assets](index=56&type=section&id=12.16%20Intangible%20Assets) The Group's net book value of intangible assets slightly decreased to **RMB 56,351 thousand** as of June 30, 2025, from **RMB 58,181 thousand** as of December 31, 2024, primarily due to amortization, while goodwill remained unchanged at **RMB 37,008 thousand** from a 2019 acquisition - The net book value of intangible assets decreased from **RMB 58,181 thousand** as of December 31, 2024, to **RMB 56,351 thousand** as of June 30, 2025[149](index=149&type=chunk) - Amortization expense for the six months ended June 30, 2025, was **RMB 2,115 thousand**, primarily recognized in administrative expenses[150](index=150&type=chunk) - Goodwill balance was **RMB 37,008 thousand**, arising from the 2019 acquisitions of Taimei Xinghuan and Beijing Nuoming Technology Co., Ltd[151](index=151&type=chunk) [Deferred Income Tax](index=58&type=section&id=12.17%20Deferred%20Income%20Tax) As of June 30, 2025, the Group had no net deferred income tax assets or liabilities, as deferred tax assets and liabilities were offset, with changes primarily related to tax losses, credit loss provisions, and lease liabilities - As of June 30, 2025, the Group had no net deferred income tax assets or liabilities[152](index=152&type=chunk) - Changes in deferred income tax assets and liabilities were primarily influenced by tax losses, credit loss provisions, and lease liabilities[153](index=153&type=chunk) [Contract Fulfilment Costs](index=60&type=section&id=12.18%20Contract%20Fulfilment%20Costs) The Group's contract fulfilment costs increased to **RMB 6,172 thousand** as of June 30, 2025, from **RMB 3,546 thousand** as of December 31, 2024, arising from customized software contracts and to be recognized as cost of sales within 2 to 6 months after performance obligations are met - Contract fulfilment costs increased from **RMB 3,546 thousand** as of December 31, 2024, to **RMB 6,172 thousand** as of June 30, 2025[154](index=154&type=chunk) - Contract fulfilment costs are recognized from costs incurred in fulfilling customized software contracts and will be recognized as cost of sales within 2 to 6 months after the related performance obligations are satisfied[154](index=154&type=chunk) [Trade and Bills Receivables](index=60&type=section&id=12.19%20Trade%20and%20Bills%20Receivables) The Group's total trade and bills receivables slightly decreased to **RMB 165,861 thousand** as of June 30, 2025, from **RMB 170,013 thousand** as of December 31, 2024, with an increase in impairment provision for trade receivables, and most receivables aged within six months - Total trade and bills receivables decreased from **RMB 170,013 thousand** as of December 31, 2024, to **RMB 165,861 thousand** as of June 30, 2025[155](index=155&type=chunk) - Impairment provision for trade receivables increased from **RMB 20,629 thousand** as of December 31, 2024, to **RMB 25,401 thousand** as of June 30, 2025[155](index=155&type=chunk) Ageing Analysis of Trade Receivables (as of June 30, 2025) | Ageing | Amount (RMB '000) | | :--- | :--- | | Within 3 months | 83,279 | | 3 to 6 months | 32,854 | | 6 months to 1 year | 31,124 | | 1 to 2 years | 28,366 | | 2 to 3 years | 11,051 | | Over 3 years | 3,681 | | **Total** | **190,355** | [Other Receivables and Prepayments](index=62&type=section&id=12.20%20Other%20Receivables%20and%20Prepayments) The Group's total other receivables and prepayments slightly decreased to **RMB 81,194 thousand** as of June 30, 2025, from **RMB 82,444 thousand** as of December 31, 2024, primarily comprising prepayments for products and services and deductible input VAT - Total other receivables and prepayments decreased from **RMB 82,444 thousand** as of December 31, 2024, to **RMB 81,194 thousand** as of June 30, 2025[158](index=158&type=chunk) - Key components include prepayments for products and services (**RMB 52,736 thousand**) and deductible input VAT (**RMB 19,578 thousand**)[158](index=158&type=chunk) [Long-term Receivables](index=63&type=section&id=12.21%20Long-term%20Receivables) The Group's long-term receivables slightly decreased to **RMB 11,839 thousand** as of June 30, 2025, from **RMB 12,712 thousand** as of December 31, 2024, primarily from installment sales contracts with terms of 1 to 5 years and significant financing components - Long-term receivables decreased from **RMB 12,712 thousand** as of December 31, 2024, to **RMB 11,839 thousand** as of June 30, 2025[160](index=160&type=chunk) - Long-term receivables primarily refer to amounts due in installments, generally over 1 to 5 years, and include a significant financing component[159](index=159&type=chunk) [Short-term Treasury Bond Investments](index=63&type=section&id=12.22%20Short-term%20Treasury%20Bond%20Investments) The Group's short-term treasury bond investments remained stable at **RMB 160,083 thousand** as of June 30, 2025, compared to **RMB 159,374 thousand** as of December 31, 2024, comprising redeemable fund products with a **3%** fixed interest return, primarily backed by short-term US treasury bonds - Short-term treasury bond investments increased from **RMB 159,374 thousand** as of December 31, 2024, to **RMB 160,083 thousand** as of June 30, 2025[161](index=161&type=chunk) - These investments comprise multiple redeemable fund products with a fixed interest return of **3%**, primarily backed by short-term US treasury bonds[161](index=161&type=chunk) [Cash and Cash Equivalents, Restricted Cash and Short-term Bank Deposits](index=64&type=section&id=12.23%20Cash%20and%20Cash%20Equivalents%2C%20Restricted%20Cash%20and%20Short-term%20Bank%20Deposits) The Group's cash and cash equivalents decreased to **RMB 253,013 thousand** as of June 30, 2025, from **RMB 319,297 thousand** as of December 31, 2024, while restricted cash significantly reduced due to resolved litigation, and short-term bank deposits with initial maturities over three months increased - Cash and cash equivalents decreased from **RMB 319,297 thousand** as of December 31, 2024, to **RMB 253,013 thousand** as of June 30, 2025[162](index=162&type=chunk) - Restricted cash significantly decreased from **RMB 5,100 thousand** as of December 31, 2024, to **RMB 100 thousand** as of June 30, 2025, primarily due to the resolution of pending litigation[163](index=163&type=chunk) - Short-term bank deposits with initial maturities exceeding three months increased from **RMB 599,920 thousand** as of December 31, 2024, to **RMB 736,071 thousand** as of June 30, 2025[162](index=162&type=chunk) [Share Capital](index=65&type=section&id=12.24%20Share%20Capital) The company's number of ordinary shares and share capital remained unchanged at **563,779,000** shares and **RMB 563,779 thousand** respectively as of June 30, 2025 - The company's number of ordinary shares was **563,779,000** and share capital was **RMB 563,779 thousand** as of January 1, 2025, and June 30, 2025, remaining unchanged[164](index=164&type=chunk) [Other Reserves](index=65&type=section&id=12.25%20Other%20Reserves) The Group's other reserves slightly increased to **RMB 2,295,802 thousand** as of June 30, 2025, from **RMB 2,295,189 thousand** as of January 1, 2025, primarily due to share-based payments - Other reserves increased from **RMB 2,295,189 thousand** as of January 1, 2025, to **RMB 2,295,802 thousand** as of June 30, 2025[165](index=165&type=chunk) - The increase was primarily attributable to share-based payments of **RMB 613 thousand**[165](index=165&type=chunk) [Warrant Liabilities](index=66&type=section&id=12.26%20Warrant%20Liabilities) The Group's warrant liabilities remained stable at **RMB 35,318 thousand** as of June 30, 2025, compared to **RMB 35,347 thousand** as of December 31, 2024, stemming from warrants issued to third-party investors in 2022 for future equity financing and classified as non-current liabilities - Warrant liabilities changed from **RMB 35,347 thousand** as of December 31, 2024, to **RMB 35,318 thousand** as of June 30, 2025[166](index=166&type=chunk) - Warrants were issued to third-party investors in 2022, granting them the right to subscribe for new shares at a preferential price in the next round of subsidiary equity financing[166](index=166&type=chunk) - As the next round of equity financing is not expected to commence before June 30, 2026, warrant liabilities are classified as non-current liabilities[166](index=166&type=chunk) [Share-based Payments](index=67&type=section&id=12.27%20Share-based%20Payments) The Group operates a share award scheme to incentivize directors, senior management, and employees, with **174,001** unvested restricted shares in the company and **450,500** in subsidiaries as of June 30, 2025, and share-based payment expenses significantly reduced to **RMB 613 thousand** for the six months ended June 30, 2025 - As of June 30, 2025, the company had **174,001** unvested restricted shares with a 3-year vesting period and an exercise price of **RMB 0.86**[171](index=171&type=chunk) - As of June 30, 2025, subsidiaries had **450,500** unvested restricted shares with a 5-year vesting period and exercise prices ranging from **RMB 1.00** to **RMB 2.00**[174](index=174&type=chunk) Share-based Payments (for the Six Months Ended June 30) | Expense Category | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Selling expenses | – | 3,099 | | Administrative expenses | 599 | 18,158 | | Research and development expenses | 14 | 985 | | **Total** | **613** | **22,242** | [Trade and Other Payables](index=69&type=section&id=12.28%20Trade%20and%20Other%20Payables) The Group's total trade and other payables decreased to **RMB 170,913 thousand** as of June 30, 2025, from **RMB 184,418 thousand** as of December 31, 2024, primarily comprising trade payables, staff salaries and benefits, and a reduced provision for pending litigation and claims, with most trade payables aged within three months - Total trade and other payables decreased from **RMB 184,418 thousand** as of December 31, 2024, to **RMB 170,913 thousand** as of June 30, 2025[176](index=176&type=chunk) - Key components include trade payables to third parties (**RMB 109,563 thousand**) and staff salaries and welfare payable (**RMB 43,426 thousand**)[176](index=176&type=chunk) - Provision for pending litigation and claims decreased from **RMB 4,313 thousand** as of December 31, 2024, to **RMB 716 thousand** as of June 30, 2025[177](index=177&type=chunk) Ageing Analysis of Trade Payables (as of June 30, 2025) | Ageing | Amount (RMB '000) | | :--- | :--- | | Within 3 months | 44,539 | | 3 to 6 months | 17,271 | | 6 months to 1 year | 28,983 | | 1 to 2 years | 18,544 | | Over 2 years | 226 | | **Total** | **109,563** | [Deferred Income](index=70&type=section&id=12.29%20Deferred%20Income) The Group's non-current deferred income remained unchanged at **RMB 7,402 thousand** as of June 30, 2025, compared to December 31, 2024, primarily representing government grants received but not yet recognized in other income - Non-current deferred income remained unchanged at **RMB 7,402 thousand** as of June 30, 2025, compared to December 31, 2024[179](index=179&type=chunk) - Deferred income primarily represents government grants received but not yet recognized in other income[179](index=179&type=chunk) [Related Party Transactions](index=71&type=section&id=12.30%20Related%20Party%20Transactions) The Group's related party transactions primarily involve key management personnel compensation, which significantly decreased to **RMB 8,669 thousand** for the six months ended June 30, 2025, from **RMB 51,380 thousand** in the prior year, mainly due to reduced share-based payments Key Management Personnel Compensation (for the Six Months Ended June 30) | Compensation Category | 2025 (RMB '000) | 2024 (RMB '000) | | :--- | :--- | :--- | | Salaries, wages and bonuses | 8,043 | 10,974 | | Contributions to retirement benefit schemes | 305 | 260 | | Other social security costs, housing benefits and other employee benefits | 321 | 278 | | Share-based payments | – | 39,868 | | **Total** | **8,669** | **51,380** | - Total key management personnel compensation significantly decreased, primarily due to share-based payments reducing from **RMB 39,868 thousand** in the same period of 2024 to zero in 2025[181](index=181&type=chunk) [Contingent Matters and Commitments](index=71&type=section&id=12.31%20Contingent%20Matters%20and%20Commitments) As of June 30, 2025, the Group had no significant contingent matters other than pending litigation and claims disclosed in Note 28(b), nor any material capital commitments - As of June 30, 2025, the Group had no significant contingent matters other than pending litigation and claims disclosed in Note 28(b)[182](index=182&type=chunk) - As of June 30, 2025, the Group had no material capital commitments[183](index=183&type=chunk) [Events After the Reporting Period](index=71&type=section&id=12.32%20Events%20After%20the%20Reporting%20Period) As of the report date, the Group had no significant events after June 30, 2025 - There were no significant events after June 30, 2025, and up to the date of this report[184](index=184&type=chunk)

Core Insights - The article discusses the challenges faced by Clinical Research Coordinators (CRCs) in managing clinical trials and how AI technology can alleviate their workload and enhance efficiency [1][5]. Group 1: Challenges Faced by CRCs - CRCs experience high work intensity, strict detail requirements, and complex coordination scenarios, which can lead to inefficiencies in clinical trial execution [1]. - The execution capability of CRCs is often reliant on personal experience and guidance from Clinical Research Associates (CRAs) and project managers (PMs), resulting in time-consuming and inefficient processes [5]. Group 2: AI Solutions for CRCs - The iSMO solution will integrate AI applications, specifically the co-box, to enhance knowledge management, data management, and on-site management for CRCs, significantly improving execution efficiency and quality [1][5]. - The "Project-Specific Knowledge Base" feature allows CRCs to quickly access project-related information, reducing internal communication time and improving overall team efficiency [2]. - The "GCP Knowledge Hub" module consolidates GCP and project execution knowledge, enabling CRCs to respond to inquiries efficiently [2]. - The AI Center Assistant feature provides CRCs with instant access to center-related information, enhancing daily work efficiency [3]. - The AI Workbench can automate routine tasks such as weekly reports and reminders, minimizing the risk of oversight [4]. Group 3: iSMO Solution Overview - The iSMO solution is a comprehensive digital SMO service platform designed to address core pain points in clinical research, including resource coverage, project management, and delivery [7]. - The platform has successfully collaborated with over 5,500 clinical research centers and delivered services to 210 clients, demonstrating its effectiveness in managing clinical trials [7]. - The three main advantages of the iSMO solution are extensive resources, controllable management, and improved data efficiency, creating a high-cost performance and stable delivery system [7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02576 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 200,592,533 | RMB | | 1 RMB | | 200,592,533 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 200,592,533 | RMB | | 1 RMB | | 200,592,533 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | ...

Core Insights - The company reported a revenue of 244 million yuan for the first half of 2025, representing a year-on-year decline of 10.5% due to internal business restructuring and industry environment impacts [1] - The company's loss decreased by 83.3% to 29.31 million yuan, with adjusted net loss (non-IFRS) at 28.70 million yuan, indicating an improvement in profit structure [1] - The core business, particularly SaaS product revenue, saw growth, increasing its share to 33.8%, while digital service revenue declined but maintained a gross margin of 41% [1] Financial Performance - The company effectively controlled expenses, with sales and administrative expenses decreasing by 26.6% and 73.4% year-on-year, respectively, contributing to improved operational efficiency [1] - As of June 30, the company held cash and cash equivalents, short-term deposits, and government bond investments totaling 1.149 billion yuan, with a current ratio of 5.66, indicating robust cash flow [1] Strategic Developments - The company has launched a "digital employee" system, embedding intelligent agents into its core platform, and is transitioning clients from "tool procurement" to "value sharing" through a dual-dimensional billing model [2] - Research and development investment accounted for over 15% of total expenditure in the first half of the year, with compliance delivery centers in China, the US, and other regions now operational [2] - The company experienced growth in overseas revenue, driven by the acceleration of Chinese innovative pharmaceutical companies entering international markets and increased demand for execution efficiency and compliance from international clients [2] Long-term Outlook - Overall, the company is optimizing its business structure and implementing an AIaaS strategy to improve profit quality, maintain stable cash flow, and accelerate overseas business expansion, laying a foundation for medium to long-term growth [2]

Core Viewpoint - Taimei Medical Technology (02576) reported a decline in revenue for the first half of 2025, primarily due to a decrease in digital service income [1] Financial Performance - Revenue for the period was approximately 244 million yuan, representing a year-on-year decrease of 10.5% [1] - The loss attributable to the company's owners was 22.802 million yuan, which narrowed by 86.68% compared to the previous year [1] - Earnings per share were reported at a loss of 0.04 yuan [1] Revenue Breakdown - The decrease in revenue was mainly attributed to a decline in income from digital services [1]

Group 1 - The core viewpoint of the article is that Taimei Medical Technology (02576) reported a decline in revenue and a reduced loss for the first half of 2025 [1] Group 2 - The company's revenue for the first half of 2025 was approximately 244 million, representing a year-on-year decrease of 10.5% [1] - The loss attributable to the company's owners was 22.802 million, which narrowed by 86.68% year-on-year [1] - The loss per share was reported at 0.04 yuan [1] - The decrease in revenue was primarily attributed to a decline in digital service income [1]

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 244,221,000, a decrease of 10.5% compared to RMB 272,784,000 for the same period in 2024[3] - Gross profit for the same period was RMB 100,188,000, representing a gross margin of 41.0%, compared to RMB 110,944,000 and a gross margin of 40.7% in 2024[3] - Operating loss improved to RMB 48,710,000, a reduction of 74.6% from an operating loss of RMB 191,995,000 in 2024[3] - Net loss for the period was RMB 29,309,000, significantly lower than the net loss of RMB 175,317,000 in the previous year, marking an 83.3% improvement[3] - Adjusted net loss (non-IFRS measure) was RMB 28,696,000, down 41.7% from RMB 49,253,000 in 2024[3] - The company reported a basic and diluted loss per share of RMB 0.04, compared to RMB 0.32 in the same period last year[4] - The company reported a net loss attributable to owners of RMB 22,802 thousand, significantly improved from a loss of RMB 171,126 thousand in the same period last year[19] - The net loss for the six months ended June 30, 2025, decreased by 83.3% to RMB 29.3 million from RMB 175.3 million for the same period in 2024[53] - Adjusted net loss (non-IFRS measure) for the six months ended June 30, 2025, was RMB 28.7 million, compared to RMB 49.3 million for the same period in 2024[54] Revenue Breakdown - Revenue from cloud software products increased to RMB 82,425 thousand for SaaS products, up 1.1% from RMB 81,564 thousand in 2024[15] - 38.7% of total revenue in the first half of 2025 came from sales of cloud software[33] - 61.2% of total revenue in the first half of 2025 was derived from providing digital services[36] - Revenue decreased by 10.5% from RMB 272.8 million for the six months ended June 30, 2024, to RMB 244.2 million for the six months ended June 30, 2025, primarily due to a decline in digital services revenue[27] - Cloud software sales revenue decreased by 3.0% from RMB 97.6 million to RMB 94.6 million, mainly due to a drop in custom product sales from RMB 16.0 million to RMB 12.2 million[43] - Digital services revenue fell by 14.8% from RMB 175.2 million to RMB 149.4 million, attributed to a challenging external environment and a strategic shift towards key clients[43] Cost and Expenses - Employee benefits expenses decreased to RMB 152,050 thousand, down 27.4% from RMB 209,643 thousand in 2024[16] - The total cost of sales and operating expenses for the six months was RMB 276,990 thousand, a reduction from RMB 481,108 thousand in 2024[16] - Selling expenses reduced by 26.6% from RMB 51.2 million to RMB 37.6 million, mainly due to a decrease in employee costs[46] - Administrative expenses decreased significantly by 73.4% from RMB 217.2 million to RMB 57.7 million, primarily due to a substantial reduction in share-based payments[47] - R&D expenses decreased by 26.0% from RMB 50.9 million to RMB 37.7 million, mainly due to a reduction in employee costs[48] Assets and Liabilities - Total assets as of June 30, 2025, were RMB 1,518,520,000, compared to RMB 1,583,197,000 as of December 31, 2024[7] - Total liabilities decreased to RMB 302,104,000 from RMB 348,624,000 in the previous year[8] - Cash and cash equivalents were RMB 253,013,000, down from RMB 319,297,000 as of June 30, 2024[7] - Non-current assets totaled RMB 84,465 thousand as of June 30, 2025, down from RMB 93,385 thousand at the end of 2024[14] - Trade receivables amounted to RMB 190,355 thousand, with a provision for impairment of RMB 25,401 thousand[22] - As of June 30, 2025, the company had current assets of RMB 1,170.8 million, with cash and cash equivalents amounting to RMB 253.0 million[55] - The current ratio as of June 30, 2025, was 5.66, compared to 5.05 as of December 31, 2024, indicating strong liquidity[55] Strategic Initiatives - The company plans to enhance AI research and development to improve overall technical strength and product competitiveness[37] - The introduction of AI-driven digital employee systems aims to transform clinical research processes and improve efficiency significantly[38] - The company is expanding internationally and establishing data and delivery centers in China, the U.S., and Singapore to support global clinical research needs[40] - The company is committed to expanding its market presence through strategic partnerships and collaborations in the healthcare sector[81] - The use of SaaS models is being explored to enhance service delivery and operational efficiency[86] - The company is actively involved in research and development to innovate new products and technologies in the medical field[82] Governance and Compliance - The company has adopted corporate governance codes to ensure shareholder rights and enhance corporate value[70] - There is currently no dividend policy in place, as the company intends to retain future profits for operations and business expansion[71] - The audit committee has reviewed the interim financial results for the six months ending June 30, 2025, and found them compliant with relevant accounting standards[74] - The company adheres to international financial reporting standards, which enhances transparency and accountability in financial reporting[82] - The board of directors consists of six executive directors and three independent non-executive directors, ensuring diverse governance[85] - The board is led by Chairman Zhao Lu, indicating strong leadership at the helm of the company[84] Future Plans and Use of Proceeds - The net proceeds from the global offering amounted to approximately HKD 259.5 million, allocated according to the intended use disclosed in the prospectus[67] - The company plans to allocate HKD 90.8 million (35%) of the net proceeds to improve and upgrade its TrialOS and PharmaOS platforms by December 31, 2029[68] - A total of HKD 77.9 million (30%) is designated to enhance core technology and R&D capabilities, expected to be utilized by December 31, 2029[68] - The company intends to strengthen its sales and marketing capabilities with an allocation of HKD 26.0 million (10%), also targeted for completion by December 31, 2029[68] - Strategic investments and acquisitions are planned with an allocation of HKD 38.9 million (15%), to be utilized by December 31, 2029[68] - Operating capital and general corporate purposes will receive HKD 25.9 million (10%), with a timeline extending to December 31, 2029[68] - The total net proceeds amount to HKD 259.5 million, with HKD 254.2 million remaining unutilized as of June 30, 2025[68]